Kathad U - Search Results

1

The acylfulvene alkylating agent, LP-184, retains nanomolar potency in non-small cell lung cancer carrying otherwise therapy-refractory mutations.

Kulkarni A, McDermott JR, Kathad U, Modali R, Richard JP, Sharma P, Bhatia K. Kulkarni A, et al. Among authors: kathad u. Oncotarget. 2021 Apr 13;12(8):791-806. doi: 10.18632/oncotarget.27943. eCollection 2021 Apr 13. Oncotarget. 2021. PMID: 33889302 Free PMC article.

2

A machine learning-based gene signature of response to the novel alkylating agent LP-184 distinguishes its potential tumor indications.

Kathad U, Kulkarni A, McDermott JR, Wegner J, Carr P, Biyani N, Modali R, Richard JP, Sharma P, Bhatia K. Kathad U, et al. BMC Bioinformatics. 2021 Mar 2;22(1):102. doi: 10.1186/s12859-021-04040-8. BMC Bioinformatics. 2021. PMID: 33653269 Free PMC article.

3

LP-184, a Novel Acylfulvene Molecule, Exhibits Anticancer Activity against Diverse Solid Tumors with Homologous Recombination Deficiency.

Kulkarni A, Zhou J, Biyani N, Kathad U, Banerjee PP, Srivastava S, Prucsi Z, Solarczyk K, Bhatia K, Ewesuedo RB, Sharma P. Kulkarni A, et al. Among authors: kathad u. Cancer Res Commun. 2024 May 6;4(5):1199-1210. doi: 10.1158/2767-9764.CRC-23-0554. Cancer Res Commun. 2024. PMID: 38630886 Free PMC article.

4

Conditional Dependency of LP-184 on Prostaglandin Reductase 1 is Synthetic Lethal in Pancreatic Cancers with DNA Damage Repair Deficiencies.

Restifo D, McDermott JR, Cvetkovic D, Dos Santos T, Ogier C, Surumbayeva A, Handorf EA, Schimke C, Ma C, Cai KQ, Olszanski AJ, Kathad U, Bhatia K, Sharma P, Kulkarni A, Astsaturov I. Restifo D, et al. Among authors: kathad u. Mol Cancer Ther. 2023 Oct 2;22(10):1182-1190. doi: 10.1158/1535-7163.MCT-22-0818. Mol Cancer Ther. 2023. PMID: 37552607 Free PMC article.

5

Preclinical Efficacy of LP-184, a Tumor Site Activated Synthetic Lethal Therapeutic, in Glioblastoma.

Lal B, Kulkarni A, McDermott J, Rais R, Alt J, Wu Y, Lopez-Bertoni H, Sall S, Kathad U, Zhou J, Slusher BS, Bhatia K, Laterra J. Lal B, et al. Among authors: kathad u. Clin Cancer Res. 2023 Oct 13;29(20):4209-4218. doi: 10.1158/1078-0432.CCR-23-0673. Clin Cancer Res. 2023. PMID: 37494541

6

Addendum: LP-284, a small molecule acylfulvene, exerts potent antitumor activity in preclinical non-Hodgkin's lymphoma models and in cells deficient in DNA damage repair.

Zhou J, Sturtevant D, Love C, Kulkarni A, Biyani N, Kathad U, Thacker E, Dave S, Bhatia K. Zhou J, et al. Among authors: kathad u. Oncotarget. 2023 Jul 20;14:722. doi: 10.18632/oncotarget.28479. Oncotarget. 2023. PMID: 37477520 Free PMC article. No abstract available.

7

LP-284, a small molecule acylfulvene, exerts potent antitumor activity in preclinical non-Hodgkin's lymphoma models and in cells deficient in DNA damage repair.

Zhou J, Sturtevant D, Love C, Kulkarni A, Biyani N, Kathad U, Thacker E, Dave S, Bhatia K. Zhou J, et al. Among authors: kathad u. Oncotarget. 2023 Jun 12;14:597-611. doi: 10.18632/oncotarget.28454. Oncotarget. 2023. PMID: 37306526 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

7 results

Search Page